Table 5.
Clinicopathological characteristics of patients and tumors according to recurrence pattern
| Early recurrence (within 5 years) | Late recurrence (after 5 years) | No recurrence | Early vs No | Late vs No | Early vs Late | |
|---|---|---|---|---|---|---|
| No. patients | 22 | 6 | 200 | |||
| Age, mean ± SD (years) | 61.5 ± 7.9 | 63.7 ± 4.5 | 62.6 ± 8.1 | 0.48 | 0.52 | 0.31 |
| Body mass index, mean ± SD | 23.7 ± 4.4 | 21.5 ± 1.9 | 24.0 ± 4.1 | 0.73 | 0.063 | 0.26 |
| Tumor category | ||||||
| 1 (≤2 cm) | 12 (55%) | 2 (33%) | 146 (73%) | 0.0071* | 0.045* | 0.95 |
| 2 (2.1–5.0 cm) | 6 (27%) | 4 (67%) | 48 (24%) | |||
| 3 (>5.0 cm) | 3 (14%) | 0 (0%) | 5 (3%) | |||
| 4 | 2 (9%) | 0 (0%) | 1 (1%) | |||
| No. positive lymph nodes | ||||||
| 0 | 11 (52%) | 3 (50%) | 152 (76%) | 0.0039* | 0.17 | 0.63 |
| 1–3 | 4 (19%) | 3 (50%) | 36 (18%) | |||
| 4–9 | 3 (14%) | 0 (0%) | 9 (5%) | |||
| ≥10 | 3 (14%) | 0 (0%) | 1 (1%) | |||
| Unknown | 1 | 0 | 2 | |||
| Tumor grade | ||||||
| 1 | 3 (14%) | 0 (0%) | 37 (19%) | 0.30 | 0.11 | 0.39 |
| 2 | 14 (64%) | 4 (67%) | 135 (68%) | |||
| 3 | 5 (23%) | 2 (33%) | 28 (14%) | |||
| Histological type | ||||||
| Invasive ductal carcinoma | 19 (86%) | 6 (100%) | 173 (87%) | 0.93 | 0.63 | 0.63 |
| Invasive lobular carcinoma | 2 (9%) | 0 (0%) | 15 (8%) | |||
| Other | 1 (5%) | 0 (0%) | 12 (6%) | |||
| ER (Allred score) | ||||||
| 3–5 | 1 (5%) | 0 (0%) | 7 (4%) | 0.66 | 0.50 | 0.70 |
| 6–8 | 21 (95%) | 6 (100%) | 193 (97%) | |||
| PR (Allred score) | ||||||
| 0, 2 | 10 (45%) | 3 (50%) | 60 (30%) | 0.32 | 0.57 | 0.98 |
| 3–5 | 4 (18%) | 1 (17%) | 53 (27%) | |||
| 6–8 | 8 (36%) | 2 (33%) | 87 (44%) | |||
| HER2 score | ||||||
| 0 | 11 (50%) | 2 (33%) | 85 (43%) | 0.86 | 0.38 | 0.46 |
| 1+ | 4 (18%) | 1 (17%) | 55 (28%) | |||
| 2+ | 4 (18%) | 2 (33%) | 47 (24%) | |||
| 3+ | 3 (14%) | 1 (17%) | 13 | |||
| Ki-67 LI | ||||||
| <14% | 9 (47%) | 2 (33%) | 124 (70%) | 0.049* | 0.060 | 0.55 |
| ≥14% | 10 (53%) | 4 (67%) | 54 (30%) | |||
| Unknown | 3 | 0 | 22 | |||
| p53 | ||||||
| 0 | 5 (26%) | 1 (17%) | 91 (53%) | <0.0001* | 0.037* | 0.73 |
| <1% | 2 (11%) | 1 (17%) | 27 (16%) | |||
| 1–9% | 1 (5%) | 1 (17%) | 26 (15%) | |||
| ≥10% | 11 (58%) | 3 (50%) | 29 (17%) | |||
| Unknown | 3 | 0 | 27 | |||
| Chemotherapy | ||||||
| None | 13 (59%) | 6 (100%) | 163 (82%) | 0.014* | 0.24 | 0.057 |
| Done | 9 (41%) | 0 (0%) | 37 (19%) | |||
| Dosing period of aromatase inhibitors, mean ± SD (months) | 24.7 ± 13.7 | 52.0 ± 19.6 | 52.6 ± 20.0 | <0.0001* | 0.85 | 0.0064* |
| Follow-up time, mean ± SD (months) | 29.7 ± 15.7 | 82.8 ± 23.9 | 80.6 ± 32.8 | |||
*
P < 0.05 is considered significant. ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2; LI, labeling index; PR, progesterone receptor.